KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Revenue (2017 - 2025)

Amneal Pharmaceuticals has reported Revenue over the past 9 years, most recently at $814.3 million for Q4 2025.

  • Quarterly results put Revenue at $814.3 million for Q4 2025, up 11.47% from a year ago — trailing twelve months through Dec 2025 was $3.0 billion (up 8.05% YoY), and the annual figure for FY2025 was $3.0 billion, up 8.05%.
  • Revenue for Q4 2025 was $814.3 million at Amneal Pharmaceuticals, up from $784.5 million in the prior quarter.
  • Over the last five years, Revenue for AMRX hit a ceiling of $814.3 million in Q4 2025 and a floor of $493.1 million in Q1 2021.
  • Median Revenue over the past 5 years was $613.4 million (2022), compared with a mean of $625.6 million.
  • Peak annual rise in Revenue hit 145.84% in 2021, while the deepest fall reached 1.09% in 2021.
  • Amneal Pharmaceuticals' Revenue stood at $536.9 million in 2021, then rose by 13.57% to $609.8 million in 2022, then rose by 1.18% to $617.0 million in 2023, then rose by 18.4% to $730.5 million in 2024, then grew by 11.47% to $814.3 million in 2025.
  • The last three reported values for Revenue were $814.3 million (Q4 2025), $784.5 million (Q3 2025), and $724.5 million (Q2 2025) per Business Quant data.